Replies to post #314875 on Avid Bioservices Inc (CDMO)

[geocappy1]

Follow the yellow brick road.

[biopharm]

THE IMMMUNOTRANSFORMERS

Partners in science Jedd Wolchok and Taha Merghoub solved a pharmacologic puzzle, to boost a cancer immunotherapy.
....
....
....

Peregrine Pharmaceuticals, now CDMO is in transition according to CEO Roger Lias and this transition will include the sale or license of the Peregrine Pharmaceuticals, now CDMO Intellectual Property Assets of PS Targeting. The problem is the R&D is hastily being cut when the Fiduciary duties of the current BODs must include the proper validation and verification of PS Targeting data/Biomarkers and that can only be maximized by knowing all the facts from the past such as the sealed to public court records from the sabotage where Peregrine Pharmaceuticals filed lawsuit vs CSM and we are missing the details that may help clear the mind of Roger Lias as he would change his residual value speeches...

Next the Biomarkers....Biomarkers and Biomarkers, all scientifically can prove out in much more detail the MOA of certain drugs and since Opdivo wants to combine with Infinity IPI549, the MOA of IPI-549 looks to infringe upon PS Targeting and why would the current BODs realize they may be just brought on for a breadcrumbed deal, with no Fiduciary duties being enforced ?? Why ??

Dr Jedd Wolchok is one that knows exactly the MOA of Bavituximab and overall, PS Targeting drugs.....

Notice how Infinity FAILS to mention the order of operations and completely fails to mention the targeting of Phosphatidylserine, and at least they were ALLOWED to stay on treatment longer, unlike some PS Targeting trials that were cut short and now the new BODs have fiduciary Duties to walk very carefully and handle the IP assets to prove out the science, to show if PS Targeting is required....which Dr Jedd Wolchok believes as with his research revealed PS Targeting removes off target TOXICITIES and increased patient responders.


[Quote]Summary of Translational Data

Peripheral blood samples from patients treated with IPI-549 were analyzed to characterize the potential mechanism of immune response. Data showed that IPI-549 treatment resulted in immune stimulation, with upregulation of interferon-gamma responsive factors and reinvigoration of exhausted T cells across multiple tumor types and dose levels. Additionally, initial translational data showed clinical benefit was associated with increased numbers of immune-stimulated monocytes, suggesting a biologic correlate in patients who remained on treatment longer. Infinity is continuing its translational analyses and expects to report additional findings in 2018.
..
...
https://www.prnewswire.com/news-releases/infinity-pharmaceuticals-reports-ipi-549-clinical-and-translational-data-from-completed-monotherapy-dose-escalation-component-of-phase-11b-clinical-study-in-patients-with-advanced-solid-tumors-at-sitc-annual-meeting-300553204.html